The publication of a research paper on RMC-6236 by Revolution Medicines in Cancer Discovery is likely to be viewed positively by investors, as it highlights the company's progress in developing its product pipeline. This kind of news typically generates optimism about the company's future prospects, potentially leading to a short-term increase in stock price.